News Headlines

  1. Lyndra Therapeutics Reports Positive Results From Pharmacokinetics (PK) Study Of Its Ultra-Long-Acting Oral Dosage Form

    Lyndra Therapeutics, which aims to make daily pills a thing of the past, has released positive results from a pharmacokinetics (PK) study of its ultra-long-acting oral dosage form.

  2. Opthea Completes Patient Recruitment Ahead Of Schedule In Phase 2b Wet AMD Clinical Trial

    Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, today announced that recruitment into the Company’s ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) is complete.

  3. TG Therapeutics Announces Phase I Study Of Novel BTK Inhibitor, TG-1701, In Patients With Relapsed Or Refractory B-Cell Malignancies Is Open For Enrollment

    TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the first Company sponsored Phase I study of its novel, orally available and covalently-bound Bruton Tyrosine Kinase (BTK) inhibitor, TG-1701, is open for enrollment for patients with relapsed or refractory B-cell malignancies.

  4. Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018

    Amgen (NASDAQ: AMGN) today announced the final report of the Open-Label Study of Long-TERm Evaluation Against LDL-C (OSLER-1), demonstrating long-term treatment with Repatha® (evolocumab) was associated with robust and consistent reductions in low-density lipoprotein cholesterol (LDL-C), with no increase in overall rates of adverse events over time and no neutralizing antibodies

  5. Aptinyx Exploratory Clinical Studies Provide First Evidence That NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity In Humans

    Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that exploratory clinical studies of its novel NMDA receptor (NMDAr) modulator, NYX-2925, provide the first evidence that oral dosing of the product candidate induces pharmacodynamic activities in humans that are understood to be NMDAr-mediated.

  6. Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity In Preclinical Tumor Model

    Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) cell therapies to fight cancer, today announced preclinical data highlighting the anti-cancer activity of engineered NK cells in a presentation at the Society of Immunotherapy for Cancer meeting being held in Washington D.C.

  7. OncoMed Announces Early Clinical Data For Anti-TIGIT Antibody

    OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced initial results from the Phase 1a dose escalation portion of a Phase 1a/b trial of etigilimab, the company’s anti-TIGIT antibody.

  8. InflaRx Completes Enrollment In Phase IIb Clinical Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa

    InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the complement system, a key component of the innate immune system, today announced that patient enrollment has been completed in the phase IIb study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients suffering from moderate or severe Hidradenitis Suppurativa (HS).

  9. Vivozon’s Non-Opioid Pain Killer Has Been Granted The FDA’s Fast Track Designation Through Regulatory Strategy Support From MMS

    MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that the company has successfully assisted Korea-based Vivozon Inc. in achieving a Fast Track Designation from the Food and Drug Administration (FDA) for VVZ-149, a non-opioid pain killer.

  10. CRF Health, A CRF Bracket Company, Sees First-In-Class eCOA Solutions Secure 15 Global Dermatology Trials

    RF Health, a CRF Bracket company, the leading provider of patient-centered eSource technology solutions for the life sciences industry, today announced the awarding of two new contracts by top-20 pharma companies, which will see the company’s innovative eCOA solutions used to capture patient reported outcomes in 15 global dermatology trials.